SCHEMBL4285091

SCHEMBL4285091

CC(C)COc1ccc(C(O)c2ccc(OCC(C)C)c(CCC(=O)O)c2)c(OCC(C)C)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOS P01100 2/20 0.61
JUN P05412 2/20 0.61
FFAR1 O14842 1/20 0.38
PPARG P37231 4/20 0.37
PPARD Q03181 4/20 0.37
PPARA Q07869 4/20 0.37
MAPT P10636 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HIF1A Q16665 1/20 0.36
PTGER1 P34995 1/20 0.36
PTGER4 P35408 1/20 0.36
PTGER3 P43115 1/20 0.36
PTGER2 P43116 1/20 0.36
POLB P06746 1/20 0.36
XDH P47989 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
ADRB3 P13945 3/20 0.35
ADRB1 P08588 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4277088 0.89 FOS (0.48) FOSJUNPPARGPPARAMAPT
SCHEMBL4281916 0.89 FOS (0.47) FOSJUNMAPTALDH1A1HIF1A
SCHEMBL4283756 0.88 FOS (0.60) FOSJUNFFAR1PPARGPPARD
SCHEMBL4421331 0.85 FOS (0.56) FOSJUNMAPTSMN1; SMN2
SCHEMBL4278052 0.84 FOS (0.55) FOSJUNFFAR1MAPTPOLB
SCHEMBL4283810 0.83 FOS (0.54) FOSJUNFFAR1PPARGPPARD
SCHEMBL27577529 0.78 FOS (0.48) FOSJUNMAPTSMN1; SMN2
SCHEMBL4276620 0.78 JUN (0.81) FOSJUNFFAR1PPARGPPARD
SCHEMBL4285922 0.78 FOS (0.64) FOSJUNFFAR1PPARGPPARD
SCHEMBL4286603 0.77 AKR1C3 (0.41) FOSJUNPPARGMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-05-07 US disclosed
US-7314888-B1 Compounds and medicinal use thereof TOYAMA CHEMICAL CO., LTD. (JP) 2008-01-01 US disclosed
EP-1127869-A1 NOVEL COMPOUNDS AND MEDICINAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2001-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF SP1, AP1G1, AP1M1 FOS 63/4885JUN 20/4885FFAR1 3706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.